The Texas Heart Institute

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Retrieved on: 
Monday, June 3, 2024
Research institute, Hematopoietic stem cell transplantation, UCB, DSM-IV codes, B cell, Bone marrow, Patient, CCBC, STTR, The Texas Heart Institute, Cancer prevention, Medical director, ALL, AML, Immune system, THI, Catalysis, Risk, Hospital, Lung, Blood, Research, CD34, CGT, Radiation, Infection, CRISPR

This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.

Key Points: 
  • This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.
  • 7 Hills Pharma aims to increase clinical utilization of cord blood resources and improve patient access to life-saving HSCT.
  • Bone marrow is the tissue that generates red blood cells, platelets, and the white blood cells that comprise the immune system.
  • Dr. Peter Vanderslice is a co-founder of 7 Hills Pharma and a pioneer of small molecule integrin activation.

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Surgery, Health Technology, General Health, Clinical Trials, Cardiology, The Alfred Hospital, USD, Multimedia, University of Queensland, The Texas Heart Institute, University, FDA, Cancer, Hospital, IDE, Artificial heart, Griffith University, Heart failure, MRFF, Fatigue, TAH, Patient, Monash University, Survival, Periodic breathing, EFS, Pharmaceutical industry

BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

Key Points: 
  • BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
  • View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
    BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
    Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR.
  • The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
  • “There is a huge gap between available treatment options and the number of patients with severe heart failure.

BiVACOR Names Veteran Medical Device Executive Jim Dillon as Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024
Health, FDA, Medical Devices, Health Technology, Clinical Trials, Cardiology, Biotechnology, Marketing, Food, Multimedia, The Texas Heart Institute, Myocardial infarction, Heart, Patient, Safety, Heart failure, TAH, Pharmaceutical industry

BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors.

Key Points: 
  • BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors.
  • “We are thrilled to have him join as CEO.”
    Over his multi-decade career, Mr. Dillon has held a series of corporate strategic and sales leadership positions as a key contributor to multiple successful medical device companies.
  • “It’s a privilege to lead the BiVACOR team at a pivotal time in the company’s history,” said Mr. Dillon.
  • The BiVACOR TAH device has the potential to truly revolutionize the field.”
    In late November, BiVACOR announced that the U.S. Food and Drug Administration approved an investigational device exemption allowing the company to conduct a first-in-human clinical feasibility study of the BiVACOR TAH.

BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

Retrieved on: 
Wednesday, December 27, 2023
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Food, The Texas Heart Institute, Ernst & Young, Pharmacotherapy, Hypertension, Heart, Entrepreneurship, Patient, Safety, Heart failure, TAH, Financial Times, Pharmaceutical industry

BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors.

Key Points: 
  • BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors.
  • Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry.
  • He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018.
  • In late 2020, Mr. Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States.

US FDA Grants the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study

Retrieved on: 
Wednesday, November 29, 2023
Cardiology, Biotechnology, FDA, Other Health, Health, General Health, Medical Devices, Research, Surgery, Science, Clinical Trials, Woman, Safety, Device, EFS, Exercise, Database, Patient, Male, The Texas Heart Institute, Heart, TAH, Heart failure, MD, Cardiac output, Dentistry, Medical device

The EFS will evaluate the safety and feasibility of BTAH as a bridge to a heart transplant in the treatment of subjects with biventricular heart failure.

Key Points: 
  • The EFS will evaluate the safety and feasibility of BTAH as a bridge to a heart transplant in the treatment of subjects with biventricular heart failure.
  • The study is anticipated to commence in 2024 and will pave the way for a subsequent pivotal study.
  • “I am eager to begin the BiVACOR Total Artificial Heart EFS to evaluate what I believe is a promising and potentially life-saving technology,” said Joseph Rogers, MD, National P.I.
  • “The FDA approval to begin The BiVACOR Total Artificial Heart EFS is a critical milestone for BiVACOR and is another validation of the remarkable work and accomplishments of the entire BiVACOR team.

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

Retrieved on: 
Monday, May 22, 2023
The Texas Heart Institute, University, Therapy, MB, MD Anderson Cancer Center, Immunotherapy, Icahn School of Medicine at Mount Sinai, Cancer, MD, Patient, Financial toxicity, Pembrolizumab, Nivolumab, Pharmaceutical industry

Immune checkpoint inhibitors, such as KEYTRUDA® (pembrolizumab) and OPDIVO® (nivolumab), command global sales of over $30 billion per annum due to their curative potential.

Key Points: 
  • Immune checkpoint inhibitors, such as KEYTRUDA® (pembrolizumab) and OPDIVO® (nivolumab), command global sales of over $30 billion per annum due to their curative potential.
  • However, up to 90% of patients with solid tumors were found not to respond, leaving these patients with limited treatment options.
  • “Developing first-in-class therapeutics, especially in Houston, is a challenging task,” said Dr. Michael S. Perry, chairman of the 7 Hills Board of Managers.
  • 7 Hills is inspired to finally deliver the full promise of immunotherapy and we are excited to demonstrate alintegimod’s distinctive benefits when combined with checkpoint blockade.”

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

Retrieved on: 
Monday, February 27, 2023
DREAM, Marketing, CHF, The Texas Heart Institute, LVEF, FACC, Knowledge, American College, MPC 75, Doctor of Philosophy, Heart failure with preserved ejection fraction, MD, Survival, Stroke, HF, MPC, MSB, Heart, MACE, Inflammation, JACC, Research, MESO, Risk, American Heart Journal, Cell, Plaque, Journal, FDA, NYHA, Myocardial infarction, Patient, LVAD, Heart failure, Regenerative medicine, Blood, Mesoblast, Cardiomyopathy, Splenic infarction, US Foods, GI, Nosebleed, Hospital, Membrane protein, Incidence, MI, Pharmaceutical industry, Medical imaging, Cardiology

NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).

Key Points: 
  • NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).
  • Locally, in the heart, the MPCs can protect cardiac muscle cells from dying and can improve blood flow and energetics.
  • In large blood vessels throughout the body, the reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.
  • “The results of DREAM-HF suggest those patients with heart failure with preserved ejection fraction (HFpEF) and other cardiomyopathies could potentially benefit from MPC therapy as well.

Texas Heart Medical Group is Now The Texas Heart Institute Center for Cardiovascular Care

Retrieved on: 
Wednesday, December 7, 2022
Heart, Physician, The Texas Heart Institute, Diagnosis, Health, Patient, Research, Memorial Hermann–Texas Medical Center, News, Surgeon, Cardiology, Education, U.S. News & World Report, Texas Medical Center, Pharmaceutical industry, Medical device

HOUSTON, Dec. 7, 2022 /PRNewswire/ -- The Texas Heart Institute® announced today that the Texas Heart Medical Group has changed its name to The Texas Heart Institute Center for Cardiovascular Care. Over the past 6 decades, The Texas Heart Institute® has been internationally recognized for delivering exceptional clinical care in a sophisticated, patient-centered atmosphere. Today, the physicians and surgeons of The Texas Heart Institute Center for Cardiovascular Care are fully integrated with The Institute providing world-class care in addition to the newest and most innovative treatments for heart and vascular disease.

Key Points: 
  • HOUSTON, Dec. 7, 2022 /PRNewswire/ -- The Texas Heart Institute announced today that the Texas Heart Medical Group has changed its name to The Texas Heart Institute Center for Cardiovascular Care.Over the past 6 decades, The Texas Heart Institute has been internationally recognized for delivering exceptional clinical care in a sophisticated, patient-centered atmosphere.Today, the physicians and surgeons of The Texas Heart Institute Center for Cardiovascular Care are fully integrated with The Institute providing world-class care in addition to the newest and most innovative treatments for heart and vascular disease.
  • The opening of The Texas Heart Institute Center for Cardiovascular Care brings together a level of expertise that attracts local, regional, and international patients.
  • The Texas Heart Institute Center for Cardiovascular Care is its clinical practice specializing in cardiovascular care in a sophisticated, welcoming, patient-centric atmosphere.
  • Fully integrated with The Texas Heart Institute's research and education arms, The Texas Heart Institute Center for Cardiovascular Care attracts local, regional, and international patients seeking excellent cardiovascular care as well as cardiologists and heart surgeons looking for expert opinions for their most challenging cases.

Global Pacemakers Pipeline Insight and Competitive Landscape 2022: Featuring Key Players Medtronic, Boston Scientific Corporation, Biotronik Se & Co, LivaNova & Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, Health, Medical Devices, Acquisition, Blood, Physician, Competitive landscape, Food, CRT, Metal electrode leadless face, Degenerative disease, UCLA, Implantable cardioverter-defibrillator, News, Heart failure, Food and Drug Administration, Ageing, Technology, FDA, High, Heart, Medtronic, Growth, Cardiac arrest, Population, THI, The Texas Heart Institute, Nature, Prevalence, Medical device, Oil, Artificial cardiac pacemaker

This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.

Key Points: 
  • This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.
  • The Pacemakers market is expected to undergo significant growth in the approaching years owning to an increasing prevalence of cardiovascular disorders around the world.
  • This report provides a detailed study of the emerging pacemakers along with competitive landscape to help better understand the emerging pacemaker devices.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

U.S. News & World Report Names Baylor St. Luke's Medical Center Among the Best in Cancer, Cardiology & Heart Surgery, Gastroenterology & GI Surgery, Geriatrics, Neurology & Neurosurgery, and Urology

Retrieved on: 
Tuesday, July 26, 2022
People, Online, Magnet, Education, Diabetes, View, TAVR, Baylor University, Physician, Twitter, Hospital, CEO, U.S. News & World Report Best Hospitals Rankings, Research, RTI, Partnership, Aortic valve, Medical Center, CHI St. Luke's Health, Chronic obstructive pulmonary disease, Adult, Magnet Recognition Program, Multimedia, U.S. News & World Report, Baylor College of Medicine, Baylor St. Luke's Medical Center, ISBN, Facebook, Policy, The Texas Heart Institute, Pneumonia, Nursing, MD, American Nurses Credentialing Center, Patient, St Luke's, Texas Medical Center, Travel, Stroke, Denton Cooley, Heart failure, COPD, RTI International, Guide, Kidney failure, Research Triangle Park, Health insurance, Medicine, News, U.S, Greater Houston, Health

HOUSTON, July 26, 2022 /PRNewswire/ -- Baylor St. Luke's Medical Center is recognized as a Best Hospital for 2022-23 by U.S. News & World Report.

Key Points: 
  • HOUSTON, July 26, 2022 /PRNewswire/ --Baylor St. Luke's Medical Center is recognized as a Best Hospital for 2022-23 by U.S. News & World Report.
  • 2 in the Houston Metro Area and No.3 in Texas, Baylor St. Luke's ranked nationally in the following six specialties:
    Cancer (Dan L Duncan Comprehensive Cancer Center), ranked No.
  • "Baylor St. Luke's Medical Center is delivering quality care and outstanding outcomes while training the next generation of physicians and health professionals."
  • Baylor St. Luke's Medical Center is an 881-bed quaternary care academic medical center that is a joint venture between Baylor College of Medicine and St. Luke's Health.